Oral GLP-1 drugs for obesity, no diabetes

Injectable semaglutide and tirzepatide get most of the attention in weight-management coverage, but a parallel development is reshaping how clinicians think about oral options for people with obesity who do not have type 2 diabetes. A network meta-analysis published in Obesity Science and Practice in August 2026 pulled together nine randomised controlled trials and 5,766 participants to compare four oral GLP-1 receptor agonists (GLP-1 RAs) head-to-head against placebo^[1].

What the network meta-analysis found

The analysis, led by A B M Kamrul-Hasan and colleagues from institutions across Bangladesh, India, Saudi Arabia, and the UK, covered trials of 20 to 72 weeks duration^[1]. The four agents studied were oral semaglutide, orforglipron, danuglipron, and lotiglipron.

High-dose oral semaglutide produced a mean body weight reduction of 11.6% relative to placebo^[1]. That figure is a network estimate; the direct phase 3 evidence from OASIS 1, published in the Lancet in 2023, found that oral semaglutide 50 mg once daily produced a mean body weight change of minus 15.1% at 68 weeks compared with minus 2.4% on placebo, a difference of 12.7 percentage points^[2]. In OASIS 1, 85% of participants on semaglutide reached at least 5% weight loss, 69% reached at least 10%, and 54% reached at least 15%^[2].

Orforglipron high-dose produced a mean body weight reduction of 11.8% in the network analysis and the greatest absolute weight loss at minus 12.2 kg^[1]. Orforglipron is a small-molecule GLP-1 receptor agonist, meaning it does not have the peptide structure of semaglutide and can be taken without the food and water restrictions that limit oral semaglutide absorption. The phase 2 trial reported in the New England Journal of Medicine in September 2023 enrolled 272 adults with obesity or overweight without diabetes and found body weight reductions ranging from 8.6% to 12.6% at 26 weeks across dose groups, compared with 2.0% on placebo^[3].

How the four agents compared

Within the network analysis, semaglutide high-dose produced the largest BMI reduction at 4.7 kg/m2 and the largest waist circumference reduction at 10.0 cm^[1]. Danuglipron high-dose, semaglutide high-dose, and semaglutide low-dose ranked highest for reaching the 5%, 10%, and 15% weight-loss thresholds respectively. Low-dose lotiglipron was the one agent that did not outperform placebo on the primary outcome.

The authors were explicit about the limits of the evidence: certainty was rated low to moderate across outcomes, and there are no published head-to-head comparisons between these four oral agents. The network estimates carry more uncertainty than direct trial comparisons would, and the trial durations varied from 20 to 72 weeks, which makes pooling the longer-horizon efficacy data difficult.

What separates oral from injectable options

The injectable semaglutide formulation (Wegovy) produced 14.9% mean weight loss at 68 weeks in the STEP 1 trial, and the subcutaneous pen is already approved for obesity management in the US, EU, and UK. Oral semaglutide (Rybelsus) is approved for type 2 diabetes but not for obesity in most jurisdictions as of writing; the OASIS 1 phase 3 data that would support an obesity indication were published in the Lancet in 2023^[2], and regulatory submissions are ongoing.

Oral formulations are attractive for patients who prefer not to self-inject and for healthcare systems that see adherence barriers with injectable regimens. The GI adverse-event profile is similar across oral and injectable GLP-1 RAs: nausea, vomiting, diarrhoea, and constipation are the most common complaints, predominantly mild to moderate in severity. In OASIS 1, gastrointestinal events occurred in 80% of the oral semaglutide group versus 46% on placebo.

What the research does not yet tell us

Long-term cardiovascular outcomes data are sparse for oral formulations in the non-diabetic population. For injectable semaglutide, the SELECT trial reported a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes. No equivalent cardiovascular outcomes trial for oral semaglutide or orforglipron in people without diabetes has reported results as of August 2026. The semaglutide regulation pages track approval status by jurisdiction.

The network meta-analysis also does not include data on weight regain after stopping, the effect in specific subgroups such as people with hepatic steatosis or sleep apnea, or comparative data against injectables. For context on how the approved injectables perform, see the semaglutide overview.

The regulatory picture

Oral semaglutide for obesity is not yet approved in the US, EU, or UK for weight management. The existing Rybelsus (oral semaglutide) label is for type 2 diabetes. Orforglipron has not received any approval as of this writing. Danuglipron trials are ongoing. Lotiglipron development was paused by Pfizer in 2023 after safety findings. Any prescribing decision, including whether to ask a clinician about access to an oral GLP-1 RA for weight management, should involve a healthcare provider who can assess individual risk and eligibility.

A ranking can guide the next research question without deciding clinical care. Direct comparative trials would need common eligibility rules, follow-up periods, outcome definitions, and adverse-event reporting before small differences between oral candidates could be interpreted with confidence.